The Lancet recently published the results of a trial (07/12/23)to assess a synbiotic preparation (SIM01) for the alleviation of Post-acute COVID-19 syndrome (PACS). PACS is a multisystemic condition with debilitating symptoms persisting beyond 4 weeks after acute SARS-CoV-2 infection. It affects 10-30% of COVID-19 patients. Common manifestations include respiratory, gastrointestinal, neuropsychiatric symptoms and fatigue. The underlying pathogenesis is not well understood.
Studies show significant alterations in the gut microbiota of PACS patients beyond 1 year after infection, including decreased diversity/richness and reduced beneficial bacteria. There is evidence linking gut dysbiosis to specific PACS symptoms.
Given the potential role of gut microbiome changes in PACS, modulation of the microbiome with probiotics or prebiotics could be a promising area of investigation for management of this complex, debilitating condition.
Further research is needed to elucidate the mechanisms, establish causality, and evaluate efficacy of microbiome-targeted interventions in improving outcomes for PACS patients.
The full report can be read here.